Naik, V. et al. 2026. Emerging Role of SGLT2 Inhibitors Beyond Glycemic Control: “Cardiovascular and Renal Benefits and Risks”. Cardiovascular Disease Prevention and Control. 1, 1 (Mar. 2026), 29–38. DOI:https://doi.org/10.64229/v3v43h95.